Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL

Blood (2024) 144 (Supplement 1): 2786.

https://doi.org/10.1182/blood-2024-208159

Published: 2024

Journal Articles

Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML

Blood (2024) 144 (Supplement 1): 2749.

https://doi.org/10.1182/blood-2024-194031

Published: 2024

Journal Articles

A Senescent Subset in Human Hematopoietic Stem Cell (HSC) Compartment As Target for Senotherapy

Laura Poisa-Beiro, Jonathan JM Landry, Bowen Yan, Michael Kardorff, Volker Eckstein, Laura Villacorta, Anne-Claude Gavin, Judith Zaugg, Vladimir Benes, Simon Raffel, Daohong Zhou, Anthony D Ho

Blood (2024) 144 (Supplement 1): 1282.

https://doi.org/10.1182/blood-2024-194004

Published: 2024

Journal Articles

NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome

Blood (2024) 144 (3): 283–295.

https://doi.org/10.1182/blood.2023022859

Published: 2024

Includes: Supplemental data

Journal Articles

TMI-Based Dose-Escalated Bone Marrow Transplantation Can Help Preserve the Bone Marrow Microenvironment and Reduce Cellular Senescence in Old Mice

Ji Eun Lim, Srideshikan Sargur Madabushi, Hemendra Ghimire, Richardson Kimberly K, Paresh Vishwasrao, Amr M H Abdelhamid, Jeffrey Wong, Cynthia Aristei, Ha-Neui Kim, Daohong Zhou, Monzr M. Al Malki, Susanta Hui

Blood (2023) 142 (Supplement 1): 3424.

https://doi.org/10.1182/blood-2023-187062

Published: 2023

Journal Articles

Targeting BCL-XL with a Novel VHL-Based BCL-XL Degrader DT-2216 in Pre-Clinical JAK2 -Mutant AML Post-MPN Models

Zhe WANG, Qi Zhang, Anna Skwarska, Cassandra L. Ramage, Guangrong Zheng, Kira Gritsman, Kapil N. Bhalla, Naveen Pemmaraju, Daohong Zhou, Jeffrey W Tyner, Marina Y. Konopleva

Blood (2023) 142 (Supplement 1): 4154.

https://doi.org/10.1182/blood-2023-178813

Published: 2023

Journal Articles

Enriched Signalling Pathways in Venetoclax-Relapsed Chronic Lymphocytic Leukemia (CLL) Cells and Targeting Using a Protac-Based Bcl-2/Bcl-Xl Degrader

Daisy Diaz Rohena, Arnau Peris Cuesta, Bailey Slawin, Janani Ravikrishnan, Chaomei Liu, Charmelle Williams, Wanyi Hu, Peiyi Zhang, Philip Thompson, William G. Wierda, Nitin Jain, Sachet Shukla, Guangrong Zheng, Daohong Zhou, Jennifer A. Woyach, Deepa Sampath

Blood (2023) 142 (Supplement 1): 4195.

https://doi.org/10.1182/blood-2023-188250

Published: 2023

Journal Articles

Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader

Daisy Diaz Rohena, Bailey Slawin, Janani Ravikrishnan, Chaomei Liu, Wanyi Hu, Peiyi Zhang, Philip A. Thompson, William G. Wierda, Nitin Jain, Guangrong Zheng, Daohong Zhou, Jennifer A. Woyach, Deepa Sampath

Blood (2022) 140 (Supplement 1): 497–498.

https://doi.org/10.1182/blood-2022-168345

Published: 2022

Journal Articles

Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells

Yannan Jia, Lina Han, Cassandra L Ramage, Connie C. Weng, Lei Yang, Simona Colla, Helen Ma, Weiguo Zhang, Michael Andreeff, Naval Daver, Nitin Jain, Naveen Pemmaraju, Kapil N. Bhalla, Satu Mustjoki, Peiyi Zhang, Guangrong Zheng, Daohong Zhou, Qi Zhang, Marina Konopleva

Blood (2022) 140 (Supplement 1): 3347–3349.

https://doi.org/10.1182/blood-2022-164541

Published: 2022

Journal Articles

Sex Dimorphism in the Bone Marrow Niche Contributes to Gender Difference in Mouse Hematopoiesis

Xiaojing Cui, Bowen Yan, Cuiping Zhang, Xinghui Zhao, Jinpeng Liu, Daheng He, Chi Wang, Daohong Zhou, Ying Liang

Blood (2022) 140 (Supplement 1): 5768–5769.

https://doi.org/10.1182/blood-2022-165785

Published: 2022

Journal Articles

Study of the Dynamics and Diversity of Hematopoietic Stem Cells during Aging and Senolytic Drug Treatment Using Single Cell Transcriptomics

Bowen Yan, Guangrong Zheng, Daohong Zhou, Olga A Guryanova

Blood (2022) 140 (Supplement 1): 5760–5761.

https://doi.org/10.1182/blood-2022-170033

Published: 2022

Journal Articles

Targeting Venetoclax-Resistant CLL By Bcl-XL Degradation

Daisy Diaz Rohena, Janani Ravikrishnan, Chaomei Liu, Guangrong Zheng, Daohong Zhou, Peiyi Zhang, William G. Wierda, Nitin Jain, Jennifer A. Woyach, Deepa Sampath

Blood (2021) 138 (Supplement 1): 2252.

https://doi.org/10.1182/blood-2021-151982

Published: 2021

Journal Articles

Targeting BCL-XL and BCL-2 By Protac 753B Effectively Eliminates AML Cells and Enhances Efficacy of Chemotherapy By Targeting Senescent Cells

Yannan Jia, Qi Zhang, Weiguo Zhang, Michael Andreeff, Nitin Jain, Peiyi Zhang, Guangrong Zheng, Daohong Zhou, Marina Konopleva

Blood (2021) 138 (Supplement 1): 2230.

https://doi.org/10.1182/blood-2021-147535

Published: 2021

Journal Articles

Long-Term Clearance of Senescent Cells Prevents the Hematopoietic Stem Cell Aging in Naturally Aged Mice

Yonghan He, MD, Jianhui Chang, Dongwen Lv, Ha-neui Kim, Maria Almeida, Xin Zhang, Xinjian Mao, PhD, Xinghui Zhao, PhD, Linheng Li, PhD, Judith Campisi, Ying Liang, MD PhD, Daohong Zhou

Blood (2019) 134 (Supplement_1): 1204.

https://doi.org/10.1182/blood-2019-123159

Published: 2019

Journal Articles

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

Yonghan He, MD, Raphael Koch, Vivekananda Budamagunta, Dongwen Lv, Sajid Khan, Xuan Zhang, Janet S Wiegand, Guangrong Zheng, David M. Weinstock, MD, Daohong Zhou

Blood (2019) 134 (Supplement_1): 303.

https://doi.org/10.1182/blood-2019-125820

Published: 2019

Journal Articles

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

Qi Zhang, PhD, Sajid Khan, PhD, Xuan Zhang, Vinitha Mary Kuruvilla, MSc, Sanaz Ghotbaldini, Julia Wells, PhD, Natalia Baran, PhDMD, Tianyu Cai, PhD, Lina Han, PhD, Adolfo Ferrando, MD, PhD, Yong-Mi Kim, MD MPH, PhD, Guangrong Zheng, Daohong Zhou, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3870.

https://doi.org/10.1182/blood-2019-124744

Published: 2019

Journal Articles

DT2216, a Synthetic Proteolytic Selectively Targeting Bcl-X L for Ubiquitination and Degradation in Tumor Cells but Not in Platelets, Is a Safer and More Potent Antitumor Agent Than Navitoclax

Sajid Khan, PhD, Xuan Zhang, BMBS, Dongwen Lv, PhD, Yonghan He, MD, Peiyi Zhang, MS, Xingui Liu, PhD, Dinesh Thummuri, PhD, Qi Zhang, PhD, Marina Y. Konopleva, MD PhD, Robert A. Hromas, MD, Guangrong Zheng, Daohong Zhou, MD

Blood (2018) 132 (Supplement 1): 2698.

https://doi.org/10.1182/blood-2018-99-114762

Published: 2018

Journal Articles

The Dosage of Pten Is Critical in Determining the Disease Severity - a Mouse Model Differentially Mimicking JMML and CMML

Yan Yan, MD, Natalia C Colorado, MD, Shelly Lensing, MS, Delli R Robinson, Nicholas J Baltz, Daohong Zhou, MD, Peter Dean Emanuel, MD, Y. Lucy Liu, MD PhD

Blood (2016) 128 (22): 1550.

https://doi.org/10.1182/blood.V128.22.1550.1550

Published: 2016

Journal Articles

Inhibition of Both Activated p38 Mapkα and mTORC1 Potentiates the Effect of SR1 on Promoting Hematopoietic Reconstitution of E x V ivo Expanded Human Umbilical Cord Blood Hematopoietic Stem Cells

Xiao Ma, Xiaoyi Li, Danyue Peng, Huifang Wang, Lei Li, Hao Zhou, Daohong Zhou, Yi Luo, Lingbo Liu

Blood (2016) 128 (22): 2173.

https://doi.org/10.1182/blood.V128.22.2173.2173

Published: 2016

Journal Articles

Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy

Y. Lucy Liu, Yan Yan, Cody Webster, Lijian Shao, Shelly Y. Lensing, Hongyu Ni, Wei Feng, Natalia Colorado, Rupak Pathak, Zhifu Xiang, Martin Hauer-Jensen, Shaoguang Li, Daohong Zhou, Peter D. Emanuel

Blood (2016) 127 (15): 1912–1922.

https://doi.org/10.1182/blood-2015-05-646216

Published: 2016

Includes: Supplemental data

NARROW

Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL

Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML

A Senescent Subset in Human Hematopoietic Stem Cell (HSC) Compartment As Target for Senotherapy

NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome

TMI-Based Dose-Escalated Bone Marrow Transplantation Can Help Preserve the Bone Marrow Microenvironment and Reduce Cellular Senescence in Old Mice

Targeting BCL-XL with a Novel VHL-Based BCL-XL Degrader DT-2216 in Pre-Clinical JAK2 -Mutant AML Post-MPN Models

Enriched Signalling Pathways in Venetoclax-Relapsed Chronic Lymphocytic Leukemia (CLL) Cells and Targeting Using a Protac-Based Bcl-2/Bcl-Xl Degrader

Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader

Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells

Sex Dimorphism in the Bone Marrow Niche Contributes to Gender Difference in Mouse Hematopoiesis

Study of the Dynamics and Diversity of Hematopoietic Stem Cells during Aging and Senolytic Drug Treatment Using Single Cell Transcriptomics

Targeting Venetoclax-Resistant CLL By Bcl-XL Degradation

Targeting BCL-XL and BCL-2 By Protac 753B Effectively Eliminates AML Cells and Enhances Efficacy of Chemotherapy By Targeting Senescent Cells

Long-Term Clearance of Senescent Cells Prevents the Hematopoietic Stem Cell Aging in Naturally Aged Mice

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

DT2216, a Synthetic Proteolytic Selectively Targeting Bcl-X L for Ubiquitination and Degradation in Tumor Cells but Not in Platelets, Is a Safer and More Potent Antitumor Agent Than Navitoclax

The Dosage of Pten Is Critical in Determining the Disease Severity - a Mouse Model Differentially Mimicking JMML and CMML

Inhibition of Both Activated p38 Mapkα and mTORC1 Potentiates the Effect of SR1 on Promoting Hematopoietic Reconstitution of E x V ivo Expanded Human Umbilical Cord Blood Hematopoietic Stem Cells

Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only